Health care; creating the Right to Try for Individualized Treatments Act; authorizing individualized investigational treatments for eligible patients. Effective date.
Impact
The enactment of SB933 is expected to significantly affect state laws regarding healthcare. It offers immunity to healthcare providers from civil liability related to patients' access to individualized investigational treatments, provided that manufacturers adhere to the act's requirements. While it aims to enhance patient autonomy in treatment decisions, it does not mandate insurers or governmental agencies to cover costs associated with these treatments or impose additional obligations on facilities.
Summary
Senate Bill 933, known as the Right to Try for Individualized Treatments Act, aims to provide patients with access to individualized investigational treatments that are not yet fully approved by regulatory agencies. The bill defines eligibility criteria for patients, permitting those with life-threatening or debilitating illnesses to seek such treatments based on recommendations from their healthcare providers and informed consent. The act stresses that the involvement of manufacturers in providing such treatments remains voluntary, hence promoting innovation while ensuring patient choice.
Sentiment
The sentiment surrounding SB933 appears generally supportive, particularly among advocates for patient rights and innovative treatment access. Proponents argue that the bill empowers patients in dire health situations to pursue potentially life-saving treatments that are tailored to their specific genetic profiles. However, some concerns have been voiced regarding the lack of mandatory coverage and the potential risk of patients incurring significant costs without sufficient protection or recourse.
Contention
Notable points of contention surrounding SB933 include the balance between patient rights and the ethical considerations of encouraging investigational treatments. Critics highlight concerns about the safety of patients who may pursue unapproved drugs without adequate regulatory oversight. The bill's limitations on healthcare provider liability could potentially minimize accountability, raising ethical questions about the provisions of experimental treatments in sensitive cases. Thus, discussions around the bill illustrate the challenges of advancing medical innovation while ensuring patient safety and informed consent.
Health care; Lori Brand Patient Bill of Rights Act of 2025; rights of patient; responsibilities of patients; rights of minors; responsibilities of parents; effective date.
Children; Children's Code; term; procedure if jury trial is waived; individualized service plan; termination of parental rights; district attorney; exceptions; informal adjustments; Office of Juvenile Affairs; effective date.
Individualized service plans; legislative intent; prepared and maintained written individualized service plan; timing requirements; standards; disputed evidence; implementation; disposition; approval; tailoring; language governs; modification; standardization; review hearings; Oklahoma Department of Mental Health and Substance Abuse Services; report; effective date.
Health care; granting certain rights and protections to health care institutions and payors; prohibiting certain discrimination and adverse actions. Effective date.
Mental health: hospitalization; person requiring treatment; revise, and modify certain procedures for treatment. Amends secs. 401, 427, 430, 461, 468, 472a & 475 of 1974 PA 258 (MCL 330.1401 et seq.).
Mental health: hospitalization; person requiring treatment; revise, and modify certain procedures for treatment. Amends secs. 401, 427, 430, 461, 468, 472a & 475 of 1974 PA 258 (MCL 330.1401 et seq.).
Health: other; individualized investigational treatment for certain patients suffering from a life-threatening or severely debilitating illness; provide for. Amends title & secs. 1, 2, 3, 4, 5, 6 & 7 of 2014 PA 345 (MCL 333.26451 et seq.) & adds sec. 2a.